Last reviewed · How we verify
Standard DAPT duration
Standard DAPT duration, marketed by Federico II University, holds a position in the cardiovascular therapeutic area. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of revenue data and key trial results, which may affect investor confidence and market adoption.
At a glance
| Generic name | Standard DAPT duration |
|---|---|
| Sponsor | Federico II University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN) (PHASE3)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina (NA)
- Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2 (NA)
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI (PHASE3)
- Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions (NA)
- OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time (NA)
- Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard DAPT duration CI brief — competitive landscape report
- Standard DAPT duration updates RSS · CI watch RSS
- Federico II University portfolio CI